Molecular testing firm Precision Genetics has chosen Isohelix’s GeneFiX Saliva RNA Collection Device for COVID-19 testing.
The device marks the latest addition to Precision Genetics’ extensive portfolio of validated COVID-19 testing options submitted under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
Tom Hole, CEO of Isohelix, said: "We are proud that our GeneFix Saliva RNA Collection Device is being used as a valuable, dependable method at the Precision Genetics testing laboratory, where a wide variety of SARS-CoV-2 assays are being implemented to contribute to the global fight against COVID-19. Precision Genetics reviewed various saliva collection kits and chose the GeneFix Saliva RNA Collection Device for its superior simplicity and reliable performance."
The addition of saliva collection to Precision Genetics’ testing capabilities comes at a time when alternative collection methods for COVID-19 testing are increasingly important. Saliva collection allows a person to expel their saliva into a tube, making it far less invasive than the nasopharyngeal (NP) collection method. In addition, saliva collection offers ease and convenience for more populations and demographics.
Nate Wilbourne, CEO of Precision Genetics, said: "Saliva collection not only reduces exposure to the SARS-CoV-2 virus for healthcare professionals supervising the collection process, but as importantly offers a less invasive and comfortable alternative for groups that might require this option.”
The GeneFix Saliva DNA/RNA Collection Devices aim to maximise the yield and quality of the DNA and RNA collected, whilst offering long term stabilisation at room temperature.
